Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Researchers develop ’genetic blueprint’ to predict response to esophageal cancer treatments

20.04.2005


For the first time, researchers appear to be able to use a comprehensive panel of genetic variants to predict how a patient with esophageal cancer will respond to a spectrum of cancer treatments.



At the annual meeting of the American Association for Cancer Research (AACR), researchers from The University of Texas M. D. Anderson Cancer Center report that six different gene variants can predict an improved outcome in patients treated with two different chemotherapy drugs and/or with radiation therapy.

For example, the researchers say that a combination of several gene variants in patients treated with one type of chemotherapy (5-FU) more than doubled survival to 51 months, compared to 25 months in patients treated with the same drug who did not have these variants.


They say the findings represent a leap forward in the goal to provide tailored therapy to individual patients because it offers a genetic blueprint for gauging the potential effectiveness of all common esophageal cancer treatment, not just an analysis of how one or two "candidate" genes respond to a single treatment.

"Our data strongly suggest that combined pathway-based analysis may provide powerful clinical outcome predictors for esophageal cancer as well as for other cancers," says the study’s lead author Xifeng Wu, M.D., Ph.D., a professor in the Department of Epidemiology.

"This points to a promising new direction for cancer pharmacogenetics," she says. "Our hope is to have a gene chip one day that can analyze a patient’s genetic makeup and help physicians predict response to a wide variety of therapeutic drugs before treatment even begins."

Esophageal cancer is highly aggressive; approximately 14,520 new esophageal cancer cases and 13,570 associated deaths are expected in 2005, according to the American Cancer Society. Almost half of new cases are diagnosed at an advanced stage, when the five-year survival rate is just 14 percent. Surgery is offered to most patients, as well as one or all of the following treatments - an anti-metabolite chemotherapy agent (5FU), an alkylating agent (cisplatin) and radiation treatment.

Knowing that variations exist in how a person biologically processes those therapies, the researchers collected tissue samples from 210 esophageal cancer patients. They then developed a "pathway analysis" that examined variants in 40 different genes believed to be involved in metabolism, DNA damage repair activity and action of these of therapies. Next, they compared differences in gene variants with outcomes in patients.

"This was like putting together a recipe, searching for different ingredients that work well together for patients," Wu says.

They found that patients with the best outcomes were those who had gene variants that were less effective at neutralizing the killing power of the cancer treatments. Conversely, patients whose genes efficiently counteracted chemotherapy and radiation treatment had shorter survival times overall.

Findings include:

  • For 5FU treatment, patients who had two different variants (AC and AA) in the MTHFR gene pathway that metabolizes folate, the drug’s active ingredient, had significantly improved survival (a median of 51 months) and a longer time to recurrence (36 months) compared to patients with the AA genotype (25 months and 17 months, respectively). "That makes sense because the AC and AA variant genes are less effective in metabolizing folate, which enables the drug to work better," Wu says.
  • Significantly reduced recurrence rates and improved survival also were seen in patients treated with cisplatin who had particular variants of a multi-drug resistance gene (MDR). Proteins produced by this gene prevent cisplatin from entering cancer cells, and variants of the gene (CT and TT) that are less effective at doing so provide more therapeutic benefit to patients, Wu says. Patients with CT variant had a median survival of 29 months and those with a TT variant survived an average of 42 months. On the other hand, patients with the CC variant survived an average of just 17 months.
  • The same pattern held true in analyzing genetic response to radiation treatment. Patients who had inherited less effective variants of a base excision repair gene (XRCC1) that repairs DNA damage from radiation exhibited longer survival. Those with the GG variant had a median survival of more than 57 months, compared to almost 23 months for patients with a GA variant and only 14 months for those with an AA variant.

The researchers also discovered an additive effect between these genes and others that conferred smaller advantages. The higher the number of beneficial variants the patient had, the longer survival was, they found.

As promising as the study is, significant hurdles remain before these findings can be incorporated into treatment, Wu says. Because more data are needed to support their findings, the investigators are accumulating a cohort of 800 esophageal patients from which they can draw a comprehensive genetic profile using blood samples.

If successful, such pathway-based analyses can be conducted for the wide variety of cancers that are treated with 5FU, cisplatin and radiation, as well as other drug treatments, Wu says.

Nancy Jensen | EurekAlert!
Further information:
http://www.mdanderson.org

More articles from Life Sciences:

nachricht A Map of the Cell’s Power Station
18.08.2017 | Albert-Ludwigs-Universität Freiburg im Breisgau

nachricht On the way to developing a new active ingredient against chronic infections
18.08.2017 | Deutsches Zentrum für Infektionsforschung

All articles from Life Sciences >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Fizzy soda water could be key to clean manufacture of flat wonder material: Graphene

Whether you call it effervescent, fizzy, or sparkling, carbonated water is making a comeback as a beverage. Aside from quenching thirst, researchers at the University of Illinois at Urbana-Champaign have discovered a new use for these "bubbly" concoctions that will have major impact on the manufacturer of the world's thinnest, flattest, and one most useful materials -- graphene.

As graphene's popularity grows as an advanced "wonder" material, the speed and quality at which it can be manufactured will be paramount. With that in mind,...

Im Focus: Exotic quantum states made from light: Physicists create optical “wells” for a super-photon

Physicists at the University of Bonn have managed to create optical hollows and more complex patterns into which the light of a Bose-Einstein condensate flows. The creation of such highly low-loss structures for light is a prerequisite for complex light circuits, such as for quantum information processing for a new generation of computers. The researchers are now presenting their results in the journal Nature Photonics.

Light particles (photons) occur as tiny, indivisible portions. Many thousands of these light portions can be merged to form a single super-photon if they are...

Im Focus: Circular RNA linked to brain function

For the first time, scientists have shown that circular RNA is linked to brain function. When a RNA molecule called Cdr1as was deleted from the genome of mice, the animals had problems filtering out unnecessary information – like patients suffering from neuropsychiatric disorders.

While hundreds of circular RNAs (circRNAs) are abundant in mammalian brains, one big question has remained unanswered: What are they actually good for? In the...

Im Focus: RAVAN CubeSat measures Earth's outgoing energy

An experimental small satellite has successfully collected and delivered data on a key measurement for predicting changes in Earth's climate.

The Radiometer Assessment using Vertically Aligned Nanotubes (RAVAN) CubeSat was launched into low-Earth orbit on Nov. 11, 2016, in order to test new...

Im Focus: Scientists shine new light on the “other high temperature superconductor”

A study led by scientists of the Max Planck Institute for the Structure and Dynamics of Matter (MPSD) at the Center for Free-Electron Laser Science in Hamburg presents evidence of the coexistence of superconductivity and “charge-density-waves” in compounds of the poorly-studied family of bismuthates. This observation opens up new perspectives for a deeper understanding of the phenomenon of high-temperature superconductivity, a topic which is at the core of condensed matter research since more than 30 years. The paper by Nicoletti et al has been published in the PNAS.

Since the beginning of the 20th century, superconductivity had been observed in some metals at temperatures only a few degrees above the absolute zero (minus...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

Call for Papers – ICNFT 2018, 5th International Conference on New Forming Technology

16.08.2017 | Event News

Sustainability is the business model of tomorrow

04.08.2017 | Event News

Clash of Realities 2017: Registration now open. International Conference at TH Köln

26.07.2017 | Event News

 
Latest News

A Map of the Cell’s Power Station

18.08.2017 | Life Sciences

Engineering team images tiny quasicrystals as they form

18.08.2017 | Physics and Astronomy

Researchers printed graphene-like materials with inkjet

18.08.2017 | Materials Sciences

VideoLinks
B2B-VideoLinks
More VideoLinks >>>